Parenteral cephalosporin classification

References

• NEWTON GGF, ABRAHAM EP: Cephalosporin C, a new antibiotic containing sulfur and D-a- aminoadipic acid. Nature (1955) 175:548–556.
   PubMed Web of Science ®Google Scholar
• BROTZU G: Ridierche su di un nuovo antibiotico. Lavori Dell Instituto D'Igiene di Cagliari (1948) p1–11.
   Google Scholar
• MORIN RB, JACKSON BG, FLYNN EH, ROESIOE RW: Chem-istry of cephalosporin antibiotics M. Chemical correla-tion of penicillin and cephalosporin antibiotics. J Am Chem Soc (1962) 84:3400–3401.
   Web of Science ®Google Scholar
• NAGARAJAN R, BOECK LD, GORMAN M, HAMILL RL, HIG-GENS CE, HOEHN MM, STARK WM, WHITNEY JG: fi-lactain antibiotics from Streptomyces. J Am Chem Soc (1971) 93:2308–2310.
   PubMed Web of Science ®Google Scholar
• NOMURA H, FUGONO T, HITAKA T, MINAMI I, AZUMA T, MORIMOTO S, MASUDA T: Semi-synthetic 13-1actam anti-biotics VII- New semi-synthetic cephalosporin derived from a-sulfonyl acetic add. Heterocycles (1974) 2:67–72.
   Google Scholar
• NOMURA H, MINAMI I, HITAKA T, FUGONO T: Semi-syn-thetic O-lactara antibiotics 8. Structure-activity relation-ships of a-sulfocephalosporins. J Antibiotics (1976) 29:928–936.
   Google Scholar
• KAISER GV, GORMAN M, WEBBER JA: Cefamandole, a review of chemistry and microbiology.J Infect Dis (1978) 137 (Suppl.) S–10–16.
   Google Scholar
• BRODGEN RN, HEEL RC, SPEIGHT TM, AVERY GS: Ce-f-uroxime: a review of its antibacterial activity, pharma-cological properties and therapeutic use. Drugs (1979) 17:233–266.
   PubMed Web of Science ®Google Scholar
• BRODGEN RN, CARMINE A, HEEL RC, MORLEY PA,SPEIGHT TM, AVERY GS: Cefoperazone: a review of its in vitro antimicrobial activity, pharmacological prop-erties and therapeutic efficacy. Drugs (1981) 22:423–460.
   PubMed Web of Science ®Google Scholar
• DORCICHEIMER W, BLUMBACH J, LATRELL R, SCHELTNE-MANN KH: Recent development in the field of 13-lactam antibiotics. Ang Chem (1985) 24:180–202.
   Google Scholar
• CAMA LD, CHRISTENSEN BG: Total synthesis of 13-lactain antibiotics. VII - Total synthesis of (±)-1-oxacepha-lothin. J. Am. Chem. Soc. (1974) 96:7582–7584.
   PubMed Web of Science ®Google Scholar
• FTRESTONES RA, FAHEY JL, MACIEJEWICZ NS, PATEL GS, CHRISTENSEN BG: Total synthesis of (±)-1-carbacefoxi-tin and cefamando1e and (±)-1-oxacefamandole. J Med. Chem. (1977) 20:551–556.
   PubMedGoogle Scholar
• HAKIMELAHI GH, KHALAFT-NEZHAD A: The synthesis of(6lr, 7R9-4-carboxy-3-hydroxy-7-phenylacetamido-2-isooxacephem. Hely Chem Acta (1984) 67:18–20
   Google Scholar
• ASZODI J, BONNET A, TEUTSCH G: Enantioselective synthesis of versatile 2-isocephem synthon. Tetrahedron (1990) 46:1579–1586.
   Web of Science ®Google Scholar
• KITANO K, NARA K, NAKAO Y: Screening of beta-lactana antibiotic using a mutant of Pseudomonas aeruginosa. Jap J. Antibiotics (1977) 30(Suppl.) S–239–247.
   Google Scholar
• SHEARER MJ, BECHTOLD H, ANDRASSY K, KODERISCH J, McCARTY PT, TREUK D, JÄHNCHEN E, RITZ E: Mechanism of cephalosporin-induced hypoprothrombinemia: re-lation to cephalosporin side chain, vitamin K metabo-lism and vitamin K status. J. Clin. Pharmacol. (1988) 28:88–95.
   PubMed Web of Science ®Google Scholar
• YAMANAKA Y, YAMAMOTO T, EGASHIRA T: Effects of cephem antibiotics on rat liver aldehyde dehydro-genases. Jap. J. Pbarmacol. (1983) 33:717–723.
   PubMedGoogle Scholar
• WATANABE NA, NAGASU T, KATSU K, KITOH K: E-0702, a new cephalosporin, is incorporated into Escberichia coil cells via the tonB dependent iron transport system. Antimicrob. Agents Chemother. (1987) 31:497–504.
   PubMed Web of Science ®Google Scholar
• LABRO MT, BRYSKIER A: Immunomodulating properties of new cephalosporins: a preliminary classification. Chimiotberapia (1987) 6 (Suppl 2):219–221.
   PubMedGoogle Scholar
• O'CALLAGHAN CH: Description and classification of the newer cephalosporins and their relationships with the established compounds. J. Antimicrob. Chemother. (1979) 5:635–671.
   Google Scholar
• O'CALLAGHAN CH: Classification of cephalosporins by their antibacterial activity and pharmacoldnetic prop-erties. J. Antimicrob. Chemother. (1975) 1 (Suppl):1–12.
   Google Scholar
• BRYSKIER A: Classification des13-lactamines. Pathol. Biol. (1984) 32:658–667.
   PubMedGoogle Scholar
• BRYSKIER A: Classification des céphalosporines et rela-tion activité structures des méthoxy-imino-aminothia-zole céphalosporines. Lyon Pharm (1983) 34:99–110.
   Google Scholar
• ASZODI J, BONNET A, CHANTOT JF, COSTEROUSSE G, TEUTSCH G: Synthesis Ind antibacterial activity of iso-cephems. In: Recent advances in the chemistry of P-lactam antibiotics. Bentley PH, Southgate R (Eds) Royal Soc. Chem-istry (1988) p350–364.
   Google Scholar
• SHARIVIA SD, MEHRA U: Studies on fused 13-lactams: synthesis of novel 1-aza-analogs of cepham. Tetrahedron Lett (1984) 25: 1849-1852.
   Google Scholar
• CAMPBELL MM, JOHNSON G, ROSS B, TEMPLEY MP: 2-aza-cephezn. Tetrahedron (1990) 46:3973–3980.
   Google Scholar
• SATOH H, TSUJI T: 1-phosphocephalosporins - I - Syn-thesis of racemic 7-unsubstituted-1-phosphadethio-3-cephem-1-oxides. Tetrahedron Lett (1984) 25: 1733-1736.
   Google Scholar
• ONO H, NOZAKI Y, KATAYAMA N, OKAZAKI H: Cephabicins, new cephem antibiotics of bacterial ori-gin L Discovery and taxonomy of the producing organ-isms and fermentation. J. Antibiotics (1984) 37:1528–1535.
   PubMed Web of Science ®Google Scholar
• BRYSKIER A, PROCYK T, LABRO MT: Cefodizime, a new 2-aminothiazoly1 cephalosporin: physicochemical properties, toxicology and structure-activity relation-ships. J. Antimicrob. Chemother. (1990) 26 (Suppl C):1–8.
   Google Scholar
• ANDRIOLE VT: Pharmacokinetics of cephalosporins in patients with normal or reduced renal function. J. Infect Dis (1978) 137 (Suppl.) S–88–97.
   Google Scholar
• WILLIAMS JD: Classification of cephalosporins. Drugs (1987) 34 (Suppl 2)15–22.
   Google Scholar
• BRYSKIER A: Une nouvelle amino-2-thiazole cépha-losporine: le celotiarn (SCE 963). Structure, propriétés physicochimiques, bactériologiques et pharmaco-cinétiques. Lyon Pharm (1983) 34:191–203.
   Google Scholar
• LE NOC P, BRYSKIER A, LE NOC D: Activité antibac-térienne in vitro d'une nouvelle céphalosporine: le cefpirome (HR 810). Comparison avec la ceftriaxone, le céfotaxime, le latamoxef et la ceftaziditne. Pathol Biol . (1986) 34:567–571.
   Google Scholar
• HARTMANN B, TOMASZ A: Altered penicillin-bindingproteins in methicillin-resistant strains ofStaphylococ-cus aureus. Antimicrob. Agents Chemother. (1981) 19:726–735.
   PubMed Web of Science ®Google Scholar
• O'CALLAGHAN CH, SYKES RB, GRIFFITHS A, THORNTON JE: Cefuroxime, a new cephalosporin antibiotic activity in vitro. Antimicrob. Agents Chemother. (1976) 9:511–519.
   PubMed Web of Science ®Google Scholar
• WEAVER SS, LEBLANC BM, BODEY GP: BLS 786 (cefora- nide), a new parenteral cephalosporin in in vitro stud- ies. Antimicrob. Agents Chemother. (1979) 15:318–322.
   PubMed Web of Science ®Google Scholar
• ACTOR P, URI JV, ZAJAC L, GUARINI JR, PHILLIPS L, PITKIN DH, BERGES DA, DUNN GL, HOOVER JRE, WEISBACH J: SKF 75073, a new parenteral broad-spectrum cepha-losporin with high and prolonged serum levels. Antimi-crob. Agents Chemother. (1977) 13:784–790.
   Web of Science ®Google Scholar
• FOURTILLAN JB, LEROY A, LEFEBVRE MA, HUMBERT G,FILLASTRE JP, REUMONT G, RAMIS N: Cross-over study of pharmacokinetics of cefonicid administered intrave-nously or intramuscularly to healthy adult humans. Eur. J. Drug Metab. Pharmacok. (1985) 10:225–230.
   PubMed Web of Science ®Google Scholar
• Yrti RD, PFEFFER M, GLICK A, VAN HARKEN DR, HOTTENDORF GH: Clinical pharmacokinetics and safety of high doses of ceforanide (BLS 786) and cefa-zolin. Antimicrob. Agents Chemother. (1979) 16:615–621.
   PubMed Web of Science ®Google Scholar
• RIPA S, LA ROSA F, PRENNA M, GHIZZA A: Ceforanide:human pharmacoltinetics after iv injection. Drugs Exptl. Clin. Res. (1982) 8:269–273.
   Google Scholar
• NEU HC: Comparison of pharmacokinetics of cefaman-dole and other cephaiosporin compounds. J. Infect. Dis. (1978) 137 (Suppl.) S–80–87.
   Google Scholar
• FOORD RD: Cefuroxitne: human pharmacokinetics. An-timicrob. Agents Chemother. (1976) 9:741–750.
   PubMed Web of Science ®Google Scholar
• ROLINSON GN: 13-lactam antibiotics. J. Antimicrob. Chemother. (1986) 17:5–36.
   PubMed Web of Science ®Google Scholar
• FILLASTRE JP, LEROY A, GODIN M, OKSENHENDLER G,HUMBERT G: Pharmacokinetics of cefoxitin sodium in normal subjects and ureamic patients. J. Antimicrob. Chemother. (1978) 4 (Suppl B):79–83.
   Google Scholar
• OIIKAWA M, ORITO M, SUGATA T, SHIMAMURA M, SAWAKI M, NAKASHITA E, KURODA K, SASAHARA K: Pharmacokinetics of cefmetazole in normal subjects and in patients with impaired renal function. Antimi-crob. Agents Chemother. (1980) 18:386–389.
   PubMed Web of Science ®Google Scholar
• RODRIGUEZ-BARBERO J, MARINO EL, DOMINGUEZ-GIL A: Pharmacokinetics of cefmetazole administered intra-muscularly and intravenously to healthy adults. Antimi-crob. Agents Chemother. (1985) 28:544–547.
   PubMed Web of Science ®Google Scholar
• SCHROGIE JJ, DAVIES RO, YEH KC, ROGERS P, HOLMES GI, SKEGGS H, MARTIN CM: Bioavallability and pharma-cokinetics of cefoxitin sodium. J. Antimicrob. Chemother. (1978) 4 (Suppl B):69–78.
   Google Scholar
• ZIMMERMAN J, COHEN A, THYRUM PT: Absolute bioavail-ability and compartmental analysis of intravenous and Intramuscular cefotetan in normal volunteers. J. Clin. Pharmacol. (1989) 29:151–157.
   PubMed Web of Science ®Google Scholar
• SMITH BR, LE FROCK JL, THYRUM PT, DORET BA, YEH C,ONESTE G, SCHWARTZ A, ZIMMERMAN JJ: C,efotetan pharmacoldnetks in volunteers with various degrees of renal function. Antimicrob. Agents Chemother. (1986) 2%887–893.
   Google Scholar
• WATANABE Y, GONDA A, KIDOKORO T: Penetration ofcefbuperazone, a new cephamycin antibiotic into hu-man peritoneal exsudate.Jap. J. Antibiotics (1980 37:261–266.
   Google Scholar
• HARA K, KOHNO S, YAMAGUCHI K, SHIMADA J: Cefpimi-zole sodium- a new cephalosporin. Drugs Today (1987) 23:321–327.
   Google Scholar
• FUKASAWA M, NOGUCHI H, OKUDA T et al.: In vitro antibacterial activity of SM-1652, a new broad spectrum cephalosporin with antipseudomonal activity. Antimi-crob. Agents Chemother. (1983) 23:195–200.
   PubMed Web of Science ®Google Scholar
• FOURTILLAN JB, BRISSON AM, BECQ-GIRAUDON B: Etude pharmacocinetique de la célopérazone (T-1551) chez l'hontme, aprés administration intraveineuse de doses de 1 gramme et 2 grammes. Dosages effectues" par chromatographic liquide haute performance. Med. Mal. Infect. (1982) 12 (Suppl):21–26.
   Google Scholar
• BRISSON AM, BRYSKIER A, MILLERIOUX L, FOURTILLAN JB: Pharmacokinetics of cefotiam administered intrave-nously and intramuscularly to healthy volunteers. An-timicrob. Agents Chemother. (1984) 26:513–518.
   PubMed Web of Science ®Google Scholar
• LAKINGS DB, FRITS JM, BROWN RJ, ALLEN HR: Pharma-cokinetics of cefpimizole in normal humans after sin-gle- and multiple-dose intravenous infusions. Antimicrob. Agents Chemother. (1984) 26:802–806.
   PubMed Web of Science ®Google Scholar
• OHKAWA M, TOKUNAGA S, SUGATA T, SHIMAMURA M, OKASHO A, HIRANO S, MATSUI H: Pharmacokinetics of cefpiramide in healthy volunteers, patients with vari-ous degrees of renal dysfunction and patients on hemodialysis. Chemotherapy (Basel) (1989) 35:416–422.
   PubMed Web of Science ®Google Scholar
• FREMALTX A, SISSIA G, ROSEMBAUM M, GESLIN P: In vitro activity of cefpirome MR 810), a new parenteral cepha-losporin against penicillin susceptible and resistant pneumococci. 32nd Mtersci. Conf Antimicrob. Agent Chemother. Anaheim 1992. Abstr. 1020.
   Google Scholar
• ENG RHK, CHERUBIN C, SMITH SM, BUCCINI F: Inoculumeffect of O-1actam antibiotics on Enterobacteriaceae Antimicrob. Agent Chemother. (1985) 28:601–606.
   PubMed Web of Science ®Google Scholar
• CARMINE AA, BRODGEN RN, HEEL RC, SPEIGH'T TM,AVERY GS: Cefotaxime: a review of its antibacterial activity, pharmacological properties and therapeutic use. Drugs (1983) 25:223–289.
   PubMed Web of Science ®Google Scholar
• LEROY A, LEGUY F, BORSA F, SPENCER GR, FILLASTRE JP,HUMBERT G: Pharmacokinetics of ceftazidlme in nor-mal and uremic subjects. Antimicrob. Agent Chemother. (1984) 25:638–642.
   PubMed Web of Science ®Google Scholar
• FOURTILLAN JB, BRYSKIER A, MIGNOT A, BORSA F, HUM-BERT G: Pharmacokinetic study of cefmenoxime (SCE-1365-CMX) in healthy adults. Am.J. Med. (1984) 77 (Suppl. 6A):28–31.
   Google Scholar
• PATEL HI, CHEN S, PARSONNET M, HACKMAN MR, BROOKS MA, KONIKOFF J, KAPLAN SA: Pharmacokinet-ics of ceftriaxone in humans. Antimicrob. Agent Chemother. (1981) 20:634–641.
   PubMed Web of Science ®Google Scholar
• BRYSKIER A, PROCYK T, TREMBLAY D, LENFANT B, FOUR-TILLAN JB: Pharmacokinetics of cefoclizime adminis-tered as a single-dose (1.0 and 2.0 g) to healthy adult volunteers. J. Antimicrob. Chemother. (1990) 26 (Suppl. C):65–70.
   Google Scholar
• NAKASHIMA M, HASHIMOTO Fl, TAKIGUCHI Y, MIZUNO A, WATANABE K, UENO K, YOSHIZUMI K: Phase I - L 105. Chemotherapy (Tokyo) (1986) 34 (Suppl. 3):133–143.
   Google Scholar
• FOURTILLAN JB, BRISSON AM: Pharmacocinétique com-parEe du moxalactam et d'autres céphalosporines. Se-maines des Hopitaux de Paris (1983) 59:1968–1971.
   PubMedGoogle Scholar
• YASUNAGA M, YAMADAD H, YOSHIDA T, UCHIDA K: Phartnacokinetics and safety of 6315 S in normal vol-unteers. 24th Intersci. Conf Antimicrob. Agent Chemother, 1984 Washington.
   Google Scholar
• NARASIDA M, ONOUE H, NAGATA W: Synthetic studies on 13-lactam antibiotics - Part 5- A synthesis of 7I3-acy-lamino-3-methy1-1-oxadethia-3-cephem-4-carboxylic acid. Heterocycles (1977) 7:839–849.
   Web of Science ®Google Scholar
• NARASIDA M, YOSHIDA T, OHTANI M, EZUMI K, TAKASUKA M: Synthesis and substituent effects on an-tibacterial activity, alkaline hydrolysis rates and infra-red absorption frequencies of some cephem analogues related to latamoxef (moxalactam). J. Med. Chem. (1983) 26:1577-1582. WODDS JS, BUENNING MK, HANASONO GK: Latamoxef-associated hypoprothrobinaemia. lancet ii(1983):408 BUENNING MK, WOLD JS: Ethanol-moxalactam interac-tions in vivo. Rev. Infect, Dis. (1982) 4 (Suppl.) S-555-563. TSUJI T, SATO H, NARASIDA M, HAMASHIMA Y, YOSHIDA T: Synthesis and antibacterial activty of 6315 S, a new member of oxacephem antibiotics. J. Antibiotics (1985) 38:466–478.
   Google Scholar
• MATSUBARA T, OTSUBO S, OGAWA A: Effects of 6315 S (flomoxef) on the alcohol-metabolizing system in rats. Chemotherapy (Tokyo) (1987) 35 (Suppl. 1):460–469.
   Google Scholar
• ANDRASSY K, KODERISH 3, GEORGES K, SONNTAG H, HIRAUCHI K: Pharmacokinetics and hemostasis follow-ing administration of a new injectable oxaoephem (6315 S, flomoxeD in volunteers and in patients with renal insufficieny. Infection (1991) 19 (Suppl. 5) S-S296–302.
   Google Scholar
• UCHIDA K, MATSUBARA T, HIRAUCHI K: Studies on oxacephem antibiotics: comparison of the effects of oxa-1 and 1-thia cephalosporins on blood coagulation activities and vitamin K metabolism in rats. JapJ. Phar-macol (1989) 50:283–288.
   PubMed Web of Science ®Google Scholar
• SHIBAHARA S, OKONOGI T, MURAI Y, INOUYE S, CHRIS-TENSEN BG: Structure-activity relationships of 20-methyloxacephalosporin. 29th Intersci. Conf Antimicrob. Agent Chemother. Houston 1989 Abstr. 358.
   Google Scholar
• OKONOGI T, SHIBAHARA S, MURAI Y, YOSHIDA T, INOUYE S, KONDO S, CHRISTENSEN BG: Synthesis and antibacterial activity of novel 2-methy1-1-oxacepha-losporin. J. Antibiotics (1990) 43:357–371.
   PubMed Web of Science ®Google Scholar
• WEISSBERGER B, ABRUZZO GK, FROMTLING RA, VALIANT ME, SHUNGU DL, GRADEBUSH HH: L-656575 (OPC-9-176): a novel oxacephern. In vitro activity against aero-bic and anaerobic clinical isolates. J. Antibiotics (1988) 41:1130–1136.
   Google Scholar
• GILFILLAN EC, PELAK AB, FROMTLING RA, BLAND J, HADLEY S, GADEBUSH HH: L-656575 (0PC-9-176): a novel oxacephem. Pharmacokinetics and experimental Chemotherapy. J. Antibiotics (1988) 41:1137–1141.
   PubMedGoogle Scholar
• SHIBARA S, OKONOGI T, MURAI Y, KUDO K, YOSHIDA T,KONDO S, CHRISTENSEN BG: Synthesis of a novel 213-methy1-1-oxacephlaosporin OCP-9-176. J. Antibiotics (1988) 41:1154–1157.
   PubMedGoogle Scholar
• OGASA T, SAITO H, HASHIMOTO Y, SATO K, HIRATA T:Synthesis and biological evaluation of optically active 3H-1-carbacephem compounds. Chem. Pharm. Bull. (1989) 37:315–321.
   PubMed Web of Science ®Google Scholar
• CHANTOT JF, ASZODI J, BONNET A, COSTEROUSSE G, TEUTSCH G: RU 45978 and RU 46069: in vitro and in vivo antibacterial activty of two new broad spectrum 'so-cephems. 28th Intersci. Conf Antimicrob. Agent Chemother. Los Angeles 1988 Abstr. 436.
   Google Scholar
• ASZODI J, BONNET A, CHANTOT JF, COSTEROUSSE G, GOUIN D'AMBRIERE 5, TEUTSCH G: Synthesis and in vitro antibacterial activity of a series of 1-dethia-2-thia-cephems (isocephems). 28th Intersci. Conf Antimicrob. Agent Chemother. Los Angeles 1988 Abstr. 435.
   Google Scholar
• KOUPAL LA, WEISSBERGER B, SHUNGU DL, WEINBERG E, GRADEBUSH H: Quartemary heterocyclylamino (3-lac-tams. IL The in vitro antibacterial properties of L 640876 a new type of 13-lactam antibiotic. J. Antibiotics (1983) 36:47–53.
   Google Scholar
• PELAK BA, GILFILLAN EC, WEISSBERGER B, GRADEBUSH H: Quarternary heterocyclylamino I3-lactams: VL In vitro and in vivo antibacterial properties of L-642946 and L-652813, a long acting cephem. J. Antibiotics (1987) 40:354–362.
   PubMed Web of Science ®Google Scholar
• NIKAIDO H, LIU W, ROSENBERG EY: Outer membrane permeability and betalactamase stability of dipolar ionic cephalosporins containing methoxyimino substi-tuents. Antimicrob. Agents Chemother. (1990) 34:337–342.
   PubMed Web of Science ®Google Scholar
• INOUE E, MITUSHASHI S: Interactions of E-1040 with cephalosporinase from Citrobacter freundii. Antimi-crob. Agents Chemother. (1990) 33:2157–2159.
   Web of Science ®Google Scholar
• BRYSKIER A, CHANTOT JF: Cefpirome (HR 810) - une nouvelle céphalosporine a large spectre. Patbol. Biol. (1985) 33:447–481.
   Google Scholar
• CHANTOT JF, BRYSKIER A. Cefpirome (HR 810) - Evalu-ation expérimentale de Factivité antibiotique in vitro et in vivo d'une nouvelle amino-2-thiazole méthoxy-imino céphalosporine. Pathol. Biol. (1985) 33:482–486.
   PubMedGoogle Scholar
• HUSSON MO, IZARD D, BRYSKIER A, LECLERC H. Anti-pseudomonal activity of HR 810. Infection (1985) 13:85–86.
   PubMed Web of Science ®Google Scholar
• NAITO T, ABURAICI S, KAMACHI H, NARITA Y, OKUMURA J, KAWAGUCHI H. Synthesis and structure-activity rela-tionships of a new series of cephalosporins, BMY-28142 and related compounds. J. Antibiotics (1986) 39:1092–1107.
   PubMed Web of Science ®Google Scholar
• EJIMA A, HAYANO T, EBATA T, NAGAHARA T, KODA H, TAGAWA H, FURUKAWA M. Synthesis and antimicrobial activity of cephalosporins with a 1-pyridiniwn substi-tuent carrying a 5-membered heterocycle at the C-3 position. J Antibiotics (1987) 40:43–48.
   Google Scholar
• KATO N, KATO H, TANAKA Y, BANDO K, WATANABE K, UENO K. In vitro activity of FK 037, a new parenteral cephalosporin against anaerobic bacteria. Antimicrob. Agents Chemother. (1993) 37:957–961.
   PubMed Web of Science ®Google Scholar
• NEU HC, SAHA G, CHIN N. In vitro activity of ME 1228, a new parenteral cephalosporin. Antimicrob. Agents Chemother. (1988) 33:1260–1267.
   Google Scholar
• ICAMIYA T, NATIO T, KM Y, KOMATU Y, SASHO M, SATO N, NAKAMLTRA T, NEGI S, MOCHIDA Y, YAMAUCHI H. Synthesis and structure-activity relationships of fluoromethoxyimino containing cephems - E-1077, a novel parenteral cephem. 30th Intersci. Conf Antimicrob. Agent Chemother., Atlanta 1990 Abstr. 447.
   Google Scholar
• SAKANE K, KAWABATA K, INAMOTO Y, OKUDA 5, KAMIMURA T, TAKAYA T. FK 518, a new parenteral antipseudomonal cephalosporin L Synthesis and struc-ture-activity relationships of 3-aminopyrazoliomethyl cephalosporin. 30th Intersci. Conf Antimicrob. Agent Chemother., Atlanta 1990 Abstr. 454.
   Google Scholar
• WATANABE N, INOUE E, KATSU K, IYOBE S, MITSUHASHI S. In vitro activity of E-1040 against imipenem-resistant Pseudomonas aeruginosa strains. J. Antimicrob. Chemother. (1992) 36:684–686.
   Google Scholar
• WATANABE NA, HIRUMA R, KATSU K. In vitro evaluationof E-1077, a new cephalosporin with broad antibacterial spectrum. Antimicrob. Agents Chemother. (1992) 36:589–597.
   Google Scholar
• MIYAKE A, YOSHIMURA Y, YAMAOKA M, NISHIMURA T,HASHIMOTO N, IMADA A. Synthesis and structure-activ-ity relationships of 3-condensed azolhun methyl cepha-losporins including SCE 2787, a new parenteral cephalosporin. 29th Intersci. Conf Antimicrob. Agent Chemother., Houston 1989 Abstr. 486.
   Google Scholar
• MINE Y, SAKAMOTO H, KAMIMURA T, WATANABE Y, MATSUMOTO Y, KUWAHARA S. FK 518, a new parenteral antipseudomonal cephalosporin II. In vitro antibacte-rial activity. 29th Intersci. Conf Antimicrob. Agent Chemother., Houston 1989 Abstr. 455.
   Google Scholar
• HOFFLER D, R011ER-TUMPACH W, KOEPPE P, WIESE K. Pharmacokinetics of SCE-2787, a new cephalosporin for intravenous administration, in healthy subjects and patients with renal failure. Acta 7berapeutica (1992) 18:117–132.
   Google Scholar
• MASS L, MALERCZYK V, VERHO M, HADJU P, SEEGER K, KLESEL N. Dose linearity testing of intravenous cefpi-rome(HR810), a novel cephalosporin derivate. Infection (1987) 15:202–206.
   PubMed Web of Science ®Google Scholar
• BARBHAIYA RH, KNUPP CA, PITTMAN KA. Effect of age and gender on pharmacokinetics of cefepime. Antimi-crob. Agents Chemother. (1992) 36:1181–1185.
   PubMedGoogle Scholar
• NAKASHIMA M, UEMATSU T, NAGASHIMA S, HIRASAWA T, TOMONO Y, OHNO T, ()KANO K, MORISHITA N. Pharmacokinetics and safety of E-1077, a novel parenteral cephem antibiotic, in healthy volunteers. 31st Intersci. coq Antimicrob. Agent Chemother., Chicago 1991 Abstr. 848.
   Google Scholar
• NAKASHIMA M, UEMATSU T, KANAMARU M, UENO K, SETOYAMA T, TOMONO Y, OHNO T, OKANO K, MORISHITA N. Phase I study of E-1040, a new parenteral cephem antibiotic. J. Clin. Pharmacol (1989) 29:144–150.
   Google Scholar
• KATSU K, KITOH K, INOUE M, MFFSUHASHI S. In vitro antibacterial activity of E-0702, a semi-synthetic cepha-losporin. Antimicrob. Agents Chemother. (1982) 22:181–185.
   PubMed Web of Science ®Google Scholar
• SPENCER RC. Catecholic P-lactams: fadlitated transport J Antimicrobial Chemother. (1990) 26:733–737.
   Google Scholar
• CLTRTIS NCA, EISENSTADT RL, EAST SJ, CORNFED RJ, WALKER LA, WHITE AJ. Iron-regulated outer membrane proteins of Eschericbia coil K-12 and mechanism of action of catechol-substituted cephalosporins. Antimi-crob. Agents Chemother. (1988) 32:1879–1886.
   PubMed Web of Science ®Google Scholar
• NIKAIDO H, ROSENBERG EY. Cir and Flu proteins in the outer membrane of Escherichia coil catalyze transport of monomeric catechols: study with [3-lactam antibiot-ics containing catechol and analogous group. J. Bacte-riol. (1990) 172:1361–1367.
   PubMed Web of Science ®Google Scholar
• MACKAY JA, HARDING SM, PALMER JL, EVANS GL. Volun-teer studies with GR 69153, a novel cephalosporin. 29th Intersci. Conf. Antimicrob. Agent Chemother, Houston 1989 Abstr. 159.
   Google Scholar
• AXELROD J, TOMCHICK L. Enzymatic O-methylation of epinephrine and other catechols. J. Biol. Chem. (1958) 233:702–705.
   PubMed Web of Science ®Google Scholar
• SILLEY P, GRIFFITHS jW, MONSEY D, HARRIS AM. Mode of action of GR 69153, a novel catechol-substituted cephalosporin and its interaction with the tonB-de-pendent iron transport system. Antimicrob. Agents Chemother. (1990) 34:1806–1808.
   PubMed Web of Science ®Google Scholar
• HARRIS AM. Catechol-substituted cephalosporins. Curr. Opin. Invest. Drugs (1993) 2:109–118.
   Google Scholar
• KAMACHI H, OKA M, NARITA Y, IIMURA S, ABURAKI S, YAMASHITA Y, TOMATSU K, OKUMURA J, NAITO T. Syn-thesis of a new series of cephalosporins having 3-sub-stituted-arnmonio-1-propenyl group as the C-3 side chain. J. Antibiotics (1990) 43:533–543.
   Google Scholar
• OKITA T, IMAE K, HASEGAWA T, IIMURA S, MASUYOSHI S, KAMACHI H, KAMEI H. Synthesis and antibacterial activity of cephalosporins having a catechol in the C3 side chain. J. Antibiotics (1990) 46:833–839.
   Google Scholar
• IMAE K, IIMURA S, HASEGAWA T, OKITA T, HIRANO M, KAMACHI H, KAMEI H. Cephalosporins having a hetero-cyclic catechol in the C3 side chain I. Enhancement of efficacy against Gram-negative bacteria. J. Antibiotics (1993) 46:840–849.
   Google Scholar
• IIMURA S, IMAE K, HASEGAWA T, OKITA T, TAMAOKA M, MURATA S, KAMACHI H, KAMEI H. Cephalosporins hav-ing a heterocyclic catechol in the C3 side chain IL Improvement of pharmacokinetic profile. J. Antibiotics (1993) 46:850–857.
   PubMed Web of Science ®Google Scholar
• COURTIEU AL, DRUGEON HB, BRYSKIER A, CHUNG SS, REYNAUD AA. Activité comparée de la cefsulodine sur les Pseudomonas aeruginosa, les Actinobacter et les entérobactéries. Pathol. Biol. (1982) 30:432–439.
   Google Scholar
• BRYSKIER A. Cefsulodine, structure, propriétés physi-cochimiques, bactériologiques et pharmacodnétiques. Lyon Pharm (1983) 34:343–355.
   Google Scholar
• BUCOURT R, HEYMES R, LUTZ A, PENASSE L, PERRONNET J. Céphalosporines a chaines amino-2-thiazoly1-4-acéty-les. Tetrahedron (1978) 34:2233–2243.
   Google Scholar
• KAMIMURA T, MATSUMOTO Y, OKADA N, MINE Y, NISHIDA M, GOTO S, KUWAHARA S. Comparison of antibacterial activity of new cephalosporin, cefti-zoxime (FK 749) with other cephalosporins. J. Antibiot-ics(1979) 32:1319–1327.
   Google Scholar
• REINER R, WEISS U, BROMBACHER U, LANZ P, MONTA-VON M, FURLENMEIER A, ANGEHERN P, PROBST PJ. Ro 13-9904/001, a novel potent long-acting parenteral cephalosporin. J. Antibiotics (1980) 33:783–786.
   Google Scholar
• OCHAI M, MORITOMO A, MIYAWAKI T, MATSHUSHITA Y, OKADA T, NATSUGARI H. KIDA M. Synthesis and struc-ture-activity relationships of 7042-(2-a.minothiazol-4-yl)acetamidokephalosporin derivatives V. Synthesis and antibacterial activity of 7f1-[2-(2-aminothiazol-4-y1)-2-methoxyiminoacetarnido] cephalosporin derivatives and related compounds. J. Antibiotics (1981) 34:171–185.
   Google Scholar
• CURRAN WV, ROSS AA. 713-[2-(2-aminothiazol-4-y1)-(Z)-2-methoxyimino acet amido]-3- [(1, 2, 3- thiadiazol- 5-y1) thicunethylkeph-3-em-4-carboxylic add. A new potent cephalosporin derivative. J. Antibiotics (1983) 36:179–180.
   Google Scholar
• BLUMBACH J, DURCICHEIMER W, EHLERS E, FLEISHMANN K, KLESEL N, LIMBERT M et al.: Cefodizime, an aminothia-zolylcephalosporin V. Synthesis and structure-activity relationships in the cefodizhne series. J. Antibiotics (1987) 40:29–42.
   PubMedGoogle Scholar
• O'CALLAGHAN CH, ACRED P, HARPER PB, RYAN DM, KIRBY SM, HARDING SM. GR 20263, a new broad-spec-trum cephalosporin with anti-pseudomonal activity. Antimicrob. Agent Chemother. (1980) 17:876–883.
   PubMed Web of Science ®Google Scholar
• LATFRELL R, BLUMBACH J, DURCKHEIMER W, FEHLHABER HW, FLEISHMANN K, KIRRSTETFER R, MENCKE B, SCHE-UNEMANN ICH, SCHRINNER E, SCHWAB W, SEEGER K, SEIBERT G, WIEDUWILT M. Synthesis and structure-ac-tivity relationships in the cefpirome series L 70[242-aminothiazol-4-y1)-(Z)-2-oxyiminoacetarnidol-3-(substi tuted-1-pyridinpmethynceph-3-em-4-carboxylates. J. Antibiotics (1988) 41:1374–1394.
   Google Scholar
• OKUMURA JS, ABURAKI H, KAMACHI H, NARITA Y, NAITO T, KAWAGUCHI H. New cephalosporin, BMY-28142 and related compounds: chemistry and preliminary evalu-ation. 23rd Intersci. Conf. Antimicrob. Agent Chemother., Las Vegas (1983) Abstr. 576.
   Google Scholar
• MATSUMOTO M, HORIMOTO H, SHIZUTA T, ISHIKAWA H, ICIKUCHI M: OPC-200005, novel parenteral cephalospor-ins - structure and activity relations. 33rd Intersci Conf. Antimicrob Agents Chemother, New Orleans 1993, Abstr. 887.
   Google Scholar
• NAICASHIMA M, UEMATSU T, TAKIGUCHI Y, OBARA M, TERAKAWA M: Pharmacokinetics and safety of FK037 in healthyvolunteers. 33rd Intersci. Conf. Antimicrob. Agents Chemother, New Orleans, 1993 Abstr 883.
   Google Scholar
• ROGGE MC, CALLERY-D'AMICO SV, CHOW AT, WONG APSELOFF G, ZINNY MA, FOWLER CL: The safety and pharmacokinetics of F1(037 in single ascending intra-venous infusions. 33rd Intersci. Conf. Antimicrob. Agents Chemother, New Orleans, 1993 Abstr.
   Google Scholar
• SPANGLER SK, APELBAUM PC, KITCH T, JACOBS MR:
   Google Scholar